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Abstract
 
CD4
 
pos
 
 TH1 T cells are considered to play a central role in a
number of human autoimmune diseases such as rheumatoid
arthritis (RA) and multiple sclerosis. Experimental treat-
ment protocols aimed at selectively eliminating CD4
 
pos
 
 T cells
thus far have yielded disappointing clinical results. Here we
analyzed phenotype and function of circulating T cells in
multiple sclerosis patients treated with the chimeric CD4
mAb cM-T412 in a randomized, double-blind, placebo-con-
trolled, magnetic resonance imaging—monitored phase II trial.
Treatment resulted in a long-lasting depletion of CD4
 
pos
 
T cells but did not affect CD8
 
pos
 
 T cell numbers. Analysis of
CD4
 
pos
 
 subpopulations showed that unprimed, CD45RA
 
pos
 
/
R0
 
neg
 
 lymphocytes were approximately three times more
sensitive to the mAb than primed, CD45RA
 
neg
 
/R0
 
pos
 
 T cells.
Notably, within the CD45RA
 
pos
 
 subset, T cells with pheno-
typic evidence of prior activation, i.e., expressing Fas, were
relatively insensitive to cM-T412, compared with Fas
 
neg
 
 cells.
Remarkably, while a decrease in the number of IL-4—pro-
ducing T helper 2 (TH2)-type cells in the anti-CD4 treated
group was observed, numbers of IFN-
 
g
 
—producing T helper
1 (TH1)-type cells remained stable, resulting in a significant
increase in the TH1/TH2 ratio. Our data show that treat-
ment with depleting CD4 mAb does not eliminate the cells
most strongly involved in the disease process, i.e., primed,
IFN-
 
g
 
—producing TH1-type cells, and may therefore give
an explanation for the lack of beneficial clinical effects of
depleting CD4 mAb in human chronic autoimmune disease.
(
 
J. Clin. Invest.
 
 1997. 99:2225—2231.) Key words: CD4 anti-
bodies, monoclonal 
 
¥ 
 
autoimmune diseases therapy 
 
¥ 
 
multi-
ple sclerosis 
 
¥ 
 
T lymphocyte subsets 
 
¥ 
 
Th1 cells
 
Introduction
 
CD4
 
pos
 
 T cells, which recognize peptide fragments that are pre-
sented in the groove of major histocompatibility complex class
II molecules (1), orchestrate cellular and humoral immune re-
actions through the secretion of immunoregulatory cytokines
and via cell—cell contact (2, 3). Based on cytokine production ca-
pacity, distinct types of differentiated helper (H) CD4
 
pos
 
 T cells
are identified (4). Typically, TH1-type cells secrete IFN-
 
g
 
 and
TNF-
 
a
 
 and are involved in cell-mediated immunity, whereas
TH2-type cells secrete IL-4 and IL-5 and exert their primary
function in humoral immune reactions (5, 6). Normally, a bal-
ance exists between these two helper T cell subsets, which is in
a considerable degree maintained by cross-regulatory mecha-
nisms. IL-4 downregulates development of TH1-type cells, and
vice versa IFN-
 
g
 
 suppresses the TH2-type response (7). Au-
toimmune diseases are believed to be dependent on activation
of TH1-type cells which is not sufficiently counterbalanced by
TH2-type cells (8, 9). Indeed, a number of experimental ani-
mal models have shown that (auto)antigen reactive CD4
 
pos
 
TH1-type cells are of crucial importance for disease induction
and disease progression (10—12). In accordance with this no-
tion, in vivo depletion of CD4
 
pos
 
 T cells interferes with disease
induction in experimental allergic encephalomyelitis (13—16),
adjuvant arthritis (17), collagen-induced arthritis (18), experi-
mental autoimmune glomerulonephritis (19), experimental
antiphospholipid syndrome, and systemic lupus erythemato-
sus (20).
Also in human autoimmune diseases a pivotal role for
CD4
 
pos
 
 T cells has been postulated (21, 22) and experimental
trials aimed at specifically attacking these cells with depleting
CD4 mAb have been initiated. Although in open studies more
or less promising results have been obtained with CD4 mAb
treatment of rheumatoid arthritis (RA) (23—25), systemic lu-
pus erythematosus (26), CrohnÕs disease
 
 
 
(26a), and multiple
sclerosis (MS)
 
1
 
 patients (27—29), in double-blind, placebo-con-
trolled, phase II trials with RA patients the efficacy appeared
to be absent or very low (30, 31). Recently, absence of thera-
peutic effect was also documented in a randomized, double-
blind, placebo-controlled, magnetic resonance imaging (MRI)-
monitored phase II trial in which MS patients were treated
with the chimeric CD4 mAb cM-T412 (32). As was also shown
in earlier studies (28, 29), in this trial, a significant and long-
lasting depletion of CD4
 
pos
 
 T cells was found in CD4 mAb—
treated patients. However, no effect could be demonstrated on
the primary measure of efficacy, the number of active lesions
on monthly gadolinium enhanced MRI over 9 mo.
To examine the cause for therapeutic ineffectiveness of de-
pleting CD4 mAb in humans, we here analyzed consequences
of CD4 mAb treatment on phenotypical and functional char-
acteristics of circulating T cells in MS patients. Our data show
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that the absence of therapeutic success coincides with a spe-
cific inability of the antibody to delete primed, IFN-
 
g
 
—produc-
ing T cells.
 
Methods
 
Study design.
 
Detailed information on the design of the trial is de-
scribed elsewhere (32, 33). In summary, a randomized, double-blind,
placebo-controlled exploratory phase II trial of the CD4 antibody
cM-T412 was set up using a parallel groups design. As primary mea-
sure of treatment efficacy, the cumulative number of active lesions
seen on monthly brain MRI, performed over 9 mo from the start of
the treatment, after baseline correction, was used.
 
Patients.
 
Analyses were carried out on 28 patients treated at the
Department of Neurology, Free University Hospital (Amsterdam,
The Netherlands), who formed a subgroup of patients from a larger
multi-center study. After randomization 13 patients received placebo,
and 15 received CD4 mAb treatment. Demographic and baseline
characteristics are given in Table I. In contrast to what was seen in the
total group of patients (32), patients in both treatment arms in this
study were also comparable with respect to relapse rate in the year
preceding inclusion (mean number
 
6
 
SD of clinical relapses in the
previous year in the placebo vs. CD4 mAb group: 1.8
 
6
 
1.3 vs. 1.5
 
6
 
1.1,
 
P
 
 
 
5
 
 0.49), and with respect to the total number of active lesions at
baseline (median number of active MR lesions at inclusion in the pla-
cebo vs. CD4 mAb group 0 vs. 1, 
 
P
 
 
 
5
 
 0.15).
 
Reagents.
 
mAbs directed against CD2 (CLB-T11.1/1, CLB-T11.1/2,
and Hik27), CD28 (CLB-CD28/1), CD8 (FITC-labeled CLB-T8/4),
and CD14 (FITC-labeled, CLB-mon/1) were generated at the Central
Laboratory of The Netherlands Red Cross Blood Transfusion Ser-
vice. PerCP-labeled CD3, CD4, and CD8 mAb, phycoerythrin (PE)-
labeled CD4 mAb, and FITC-labeled CD3 mAb were purchased from
Becton Dickinson Immunocytometry Systems (San Jose, CA). PE-
labeled CD45RA mAb (2H4-RD1) was obtained from Coulter Corp.
(Miami, FL). FITC-labeled CD45R0 mAb (UCHL-1) and bioti-
nylated IgG1 control mAb were from Dako (Glostrup, Denmark),
and FITC-labeled CD95 (Fas) mAb was purchased from Immuno-
tech S.A. (Marseille, France). Streptavidin-PE was obtained from
Molecular Probes (Leiden, The Netherlands). Biotinylated 
 
a
 
IFN-
 
g
 
mAb was purchased from Dr. P. van der Meide (Biomedical Primate
Research Centre, RØswØk, The Netherlands) and biotinylated 
 
a
 
IL-4
mAb was kindly provided by Dr. T.C.T.M. van der Pouw-Kraan (Cen-
tral Laboratory of The Netherlands Red Cross Blood Transfusion Ser-
vice, Amsterdam, The Netherlands).
PMA (CMC Cancer Research, Katonah, NY) and ionomycin (Cal-
biochem, La Jolla, CA) were prepared as stock solutions in DMSO,
stored at 
 
2
 
20
 
8
 
C and diluted properly before use.
 
Blood samples and cell separation.
 
At each visit venous blood
was collected in evacuated blood collection tubes (Vacutainer, Bec-
ton Dickinson, Meylan, France) containing sodium heparin (143 USP
units). The samples were kept at room temperature and processed
within 24 h.
PBMC were isolated from heparinized blood by Ficoll-Isopaque
density gradient centrifugation and were cryopreserved immediately.
To minimize interassay variability, samples from all time points from
individual patients were analyzed in one experiment. Viability of the
cells was 
 
.
 
 95%, as indicated by trypan blue exclusion.
 
Standard culture technique.
 
PBMC (25 
 
3
 
 10
 
5
 
 cells/ml) were cul-
tured in IMDM, supplemented with 10% FCS, penicillin, streptomy-
cin, and 
 
b
 
-mercaptoethanol, in a final volume of 200 
 
m
 
l, and stimu-
lated in triplicate cultures with a triplet of CD2 mAb (CLB-T11.1/1,
CLB-T11.2/1, and Hik27; all 5 
 
m
 
g/ml) in the presence of CD28 mAb
CLB-CD28/1 (5 
 
m
 
g/ml) (34) in flat-bottom microtiter plates (Greiner,
Langenthal, Switzerland). Cells cultured without stimuli served as
negative controls.
The proliferative response (cpm) was measured after 4 d of cul-
ture by means of incorporation of [
 
3
 
H]thymidine. 0.4 mCi/well of
[
 
3
 
H]thymidine (200 mCi/mmol; Amersham, Buckinghamshire, United
Kingdom) was added 24 h before harvesting.
 
Membrane phenotyping.
 
PBMC were washed twice with PBS
supplemented with 0.5% BSA and Na-azide (5 
 
m
 
g/ml). Immunofluo-
rescence staining was performed by incubation of PBMC with satu-
rating amounts of combinations of PerCP-, FITC-, and PE-labeled
mAb in PBS/BSA. Stained cells were washed twice and 10
 
4
 
 viable
lymphocytes were analyzed using a fluorescence activated cell sorter
(FACS
 
¤
 
; Becton Dickinson, Sunnyvale, CA). Results are given as the
absolute number of cells per mm
 
3
 
 blood. For the different T cell sub-
sets these numbers were calculated using the total number of either
CD3
 
pos
 
 or CD4
 
pos
 
 T cells per mm
 
3
 
 blood.
 
Flow cytometric measurement of intracellular cytokine produc-
tion.
 
Measurement of cytokine production was performed as previ-
ously described (35, 36). Briefly, 0.5 
 
3
 
 10
 
6
 
 cells/ml were stimulated
for 4 h with PMA (1 ng/ml) and ionomycin (1 
 
m
 
M) in the presence of
the protein-secretion inhibitor monensin (1 
 
m
 
M). All subsequent
steps were performed at 4
 
8
 
C. After cell surface staining with CD3-
FITC, cells were washed twice with PBS and fixated with PBS/4%
paraformaldehyde (5 min). Fixation was followed by permeabiliza-
tion with PBS/0.1% saponin (Sigma)/10% human pooled serum (10
min). For all subsequent washing and incubation steps, PBS/0.1% sa-
ponin/0.5% BSA was used. Staining of the cytoplasm with bioti-
nylated cytokine mAb (IL-4, IFN-
 
g
 
; both 5 
 
m
 
g/ml) was followed by
incubation with streptavidin-PE (20 min). Analysis was performed as
described for the measurement of membrane markers.
 
Statistical analysis.
 
Differences between groups at baseline were
analyzed using StudentÕs 
 
t
 
 test, WilcoxonÕs test, or 
 
x
 
2
 
 test. Repeated
measurements MANOVA with age as a covariate was used to evalu-
ate treatment effects. We considered 
 
P 
 
values 
 
,
 
 0.05 to be statisti-
cally significant.
 
Results
 
CD4 mAb cM-T412 induces a long-lasting specific depletion of
CD4
 
pos
 
 T cells.
 
Treatment with the CD4 mAb resulted in a
significant reduction in absolute numbers of circulating CD3
 
pos
 
T cells (Fig. 1 
 
a
 
, 
 
P
 
 
 
5
 
 0.004). Within the total CD3
 
pos
 
 T cell pop-
ulation the mAb induced a significant and progressive decline
 
Table I. Demographic and Baseline Characteristics of Patients 
in Both Treatment Arms
 
Variable Placebo Anti-CD4
 
P
 
 value
 
Sex
Female 9 6
Male 4 9 0.13
Disease type
Relapsing remitting 8 7
Secondary progressive 5 8 0.44
Age (yr)* 36.6
 
6
 
8.5 33.7
 
6
 
6.8 0.34
Disease duration (yr)* 5.8
 
6
 
7.1 3.2
 
6
 
3.0 0.23
Number of clinical relapses previous year* 1.8
 
6
 
1.3 1.5
 
6
 
1.1 0.49
EDSS
 
à
 
 progression previous year
 
⁄
 
1.0 1.5 0.33
EDSS at inclusion
 
i
 
5.5 5.5 0.85
CD4 cell numbers/mm
 
3
 
 at inclusion* 985
 
6
 
300 810
 
6
 
237 0.10
Presence of active MR lesions at inclusion
Present 4 9
Absent 9 6 0.13
Number of active MR lesions at inclusion
 
⁄
 
0 1 0.15
*Mean
 
6
 
SD; 
 
à
 
EDSS, Expanded Disability Status Scale; 
 
⁄
 
median;
 
i
 
inclusion: month 0.
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in CD4
 
pos
 
 T cell numbers which was most prominent until
month 4 (to 30% of the pretreatment level, Fig. 1 
 
b
 
, 
 
P
 
 
 
,
 
0.001), at which time point CD4 mAb treatment for the major-
ity of the patients was interrupted or discontinued (32). A re-
markable finding was that, long after termination of treatment,
CD4
 
pos
 
 T cell numbers remained low. 18 mo after cessation of
treatment CD4
 
pos
 
 T cell numbers were still reduced to 
 
z
 
 39%
of the pretreatment level. CD8 numbers showed a slight in-
crease in the CD4 mAb—treated group (to 128% of the pre-
treatment level at month 18, Fig. 1 
 
c
 
), but this was not signifi-
cantly different from the placebo-treated group.
Because monocytes also express the CD4 antigen, albeit at
lower levels than T cells, we investigated whether these cells
were affected by treatment with the CD4 antibody. However,
at none of the time points were differences seen between the
CD4 mAb—treated group and the placebo-treated group in the
number of monocytes per mm
 
3 
 
blood (data not shown).
 
CD4 mAb treatment does not affect T cell reactivity in a
quantitative fashion.
 
In HIV-1 infection numeric depletion of
the CD4
 
pos
 
 T cell compartment coincides with a diminished
ability of T cells to proliferate in vitro (37, 38). To investigate
whether treatment with CD4 mAb had a similar effect on T
cell reactivity, T cell proliferation in vitro was analyzed. These
assays were performed in standard cultures, using isolated
PBMC, under optimal stimulation conditions, in order to mea-
sure the response per standard amount of PBMC (39). There
were no differences in proliferative capacity of circulating T
cells between the two groups as a result of treatment (Fig. 2).
Therefore, we conclude that CD4 mAb treatment does not af-
fect reactivity of the remaining circulating T cells in a quantita-
tive way.
 
Distinct sensitivities of unprimed and primed CD4
 
pos
 
 T cells
for depleting CD4 mAb.
 
Next, to more precisely define the
target cells of the CD4 mAb we investigated if different sub-
sets of CD4
 
pos
 
 T cells are equally affected by CD4 mAb treat-
ment. Triple-color immunofluorescence analysis revealed that
in placebo-treated patients, numbers of unprimed CD4
 
pos
 
CD45RA
 
pos
 
/R0
 
neg
 
 and primed CD4
 
pos
 
CD45RA
 
neg
 
/R0
 
pos
 
 T cells
(40) remained constant during the study period (Fig. 3 
 
a
 
). At
baseline the CD4 mAb—treated group had relatively more un-
primed than primed circulating CD4
 
pos
 
 T cells (Fig. 3 
 
b; NS).
Figure 1. Depletion of CD4pos T cells in peripheral blood of CD4 
mAb—treated MS patients. Mean numbers (6SD) of T cells per mm3 
blood are given for the placebo-treated group (n 5 13; open circles) 
and the CD4 mAb—treated group (n 5 15; closed triangles). (a) Mean 
CD3 numbers in the CD4 mAb—treated group are decreased to
z 53% of the baseline level at month 4, and to 68% at month 18. The 
difference with the placebo-treated group is statistically significant. 
(b) A significant decline in CD4pos T cell numbers in the CD4 mAb—
treated group in comparison with the placebo-treated group. At 
month 4 mean CD4pos T cell numbers are decreased to z 30% of the 
baseline level. Strikingly, at month 18, long after termination of treat-
ment, mean CD4pos T cell numbers are still reduced to z 39% of the 
pretreatment level. (c) CD8pos T cell numbers are not affected by the 
treatment.
Figure 2. Mean proliferative capacity of circulating T cells in stan-
dard cultures (per standard amount of PBMC) is not decreased in the 
CD4 mAb—treated group (closed triangles) and is not different from 
that of the placebo-treated group (open circles). T cells were stimu-
lated with a triplet of CD2 mAb in combination with CD28 mAb.
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Remarkably, although absolute numbers of both subsets de-
clined as a result of CD4 mAb treatment, the decline was
much more pronounced in the CD4posCD45RApos/R0neg subset
(at month 4 to 18% of the pretreatment level, P , 0.001) as
compared with the CD4posCD45RAneg/R0pos subset (at month
4 to 59% of the pretreatment level, P 5 0.002). As a conse-
quence, the ratio CD45RApos/CD45RAneg CD4pos T cells was
reversed, which remained so until the end of the study period.
After termination of treatment, numbers of both CD45RApos
and CD45RAneg CD4pos T cells increased in parallel.
When unprimed, naive CD4pos T cells are activated, the Fas
antigen is rapidly upregulated (41). Consequently, a further
subdivision can be made within the CD4posCD45RApos/R0neg
subset based on Fas expression. Fasneg cells may be regarded
as truly naive CD4pos T cells, whereas Fas-expressing T cells
are likely to have been recently activated in vivo. This type of
analysis showed that CD4 mAb treatment resulted in a sharp
decline in the number of CD4posCD45RAposFasneg T cells (Fig.
3 c, P 5 0.002), while the decline in the number of CD4pos
CD45RApos Faspos T cells was much less pronounced (Fig. 3
d, NS).
IFN-g—producing T cells are not affected by CD4 mAb
treatment. Secretion of TH1 and TH2 cytokines, a qualitative
feature of T cell function, is largely restricted to the primed
CD4pos T cell subset (36, 42). Since, as we have already men-
tioned, autoimmune diseases are believed to be dependent on
the activation of IFN-g—producing TH1-type cells, we investi-
gated, taking into account the above documented relatively
low sensitivity of primed T cells to therapy, whether CD4 mAb
treatment would differentially affect TH1- and TH2-type cells.
For this we measured absolute numbers of IFN-g— and IL-4—
producing T cells using flow cytometry (35, 36). IFN-g— and
IL-4—producing T cells remained constant in the placebo group
over time (Fig. 4, a and b). Numbers of IL-4—producing CD3pos
T cells showed an almost 50% decline in the CD4 mAb—
treated group (Fig. 4 b, NS), which is comparable with the de-
cline seen in the CD4posCD45RAneg/R0pos T cells. Remarkably,
however, numbers of IFN-g—producing CD3pos T cells re-
mained relatively stable over time in the CD4 mAb—treated
group (Fig. 4 a, NS). As a result, treatment with CD4 mAb re-
sulted in a significant increase in the TH1/TH2 ratio (Fig. 4 c,
P 5 0.035).
Discussion
Analysis of the T cell compartment in MS patients treated with
the chimeric monoclonal antibody cM-T412 shows that the
CD4 mAb induces a long-lasting selective depletion of the cir-
culating CD4pos compartment (Fig. 1 and reference 32). Re-
population studies in mice and in patients undergoing inten-
sive chemotherapy (43, 44) have shown that CD4pos T cell
repopulation is inversely correlated with age, and that rapid
reconstitution of this pool requires residual thymic function.
Because even young adults already have relative deficiencies
in this thymus-dependent pathway, it is therefore not surpris-
Figure 3. Preferential deletion 
of unprimed CD4pos T cells 
while primed CD4pos T cells are 
relatively resistant. Numbers of 
both CD4posCD45RApos/R0neg 
(open squares) and 
CD4posCD45RAneg/R0pos 
(closed diamonds) T cells re-
main relatively stable in the pla-
cebo-treated group (a), while in 
the CD4 mAb—treated group (b) 
CD4posCD45RApos/R0neg are 
more depleted than 
CD4posCD45RAneg/R0pos T 
cells. Differences between 
groups were significant for both 
parameters (CD4posCD45RApos/
R0neg T cells: P , 0.001, 
CD4posCD45RAneg/R0pos T cells: 
P 5 0.002). Within the 
CD4posCD45RApos subset no 
changes were found in both
Fasneg (open triangles) and Faspos 
(closed squares) T cells in the 
placebo-treated group (c). In the 
CD4 mAb—treated group a far 
more vigorous depletion of 
CD4posCD45RAposFasneg T cells 
occurs as compared with the 
CD4posCD45RAposFaspos T cells 
(d). Differences between 
groups were significant for 
CD4posCD45RAposFasneg T cells 
(P 5 0.002), but not for 
CD4posCD45RAposFaspos T cells.
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ing to find that the CD4pos T cell depletion lasted so long in our
anti-CD4—treated group. Furthermore, the fact that reconstitu-
tion of CD4posCD45R0pos T cells occurs in parallel with that of
the CD4posCD45RApos/R0neg T cells is in concordance with the
notion that CD4pos T cell recovery mainly consist of the ap-
pearance of CD4posCD45RApos/R0neg T cells in the circulation
(44), and favors the hypothesis that the majority of the circu-
lating CD4posCD45R0pos T cells are generated by priming of
CD4posCD45RApos/R0neg T cells, rather than from the division
of CD4posCD45R0pos T cells.
The blind homeostasis model predicts that in a given indi-
vidual a constant number of circulating CD3pos lymphocytes is
maintained irrespective of CD4pos or CD8pos phenotype (45,
46) and implies that in case of CD4pos T cell loss, such as in
HIV-1 infection, both CD4pos and CD8pos T cells will be pro-
duced in increasing amounts until the CD3pos T cell steady
state is restored. Because of the effect of HIV-1 on CD4pos, but
not on CD8pos T cells, this would then result in CD8pos T cell
lymphocytosis in the circulation. However, the data from the
CD4 mAb—treated patients in this study show that although
the loss in CD4pos T cell numbers is pronounced, this is not
compensated by an increase in CD8pos T cell numbers, not
even in the long term. Consequently, numbers of CD3pos T
cells are significantly reduced after treatment. It is likely that
in HIV-1 infection other factors, such as continuous antigenic
pressure and bystander activation through regulatory cyto-
kines, contribute to the CD8pos lymphocytosis (47). Based on
the data presented here we feel that the blind homeostasis
model needs reconsideration.
Our data demonstrate a differential sensitivity of unprimed
CD45RApos versus primed CD45RAnegCD4pos T cells for
depletion by the cM-T412 mAb. The fact that within the
CD4posCD45RApos subpopulation Fasneg T cells are more sen-
sitive to treatment than Faspos T cells shows that the depletion
is not simply related to expression of CD45RA, but that actu-
ally CD4pos T cells which have not yet been activated in vivo
are most sensitive to the depleting effect of the mAb. Also
within the CD4posCD45RAneg T cell subset, a distinction in
sensitivity for the CD4 mAb could be made on the basis of
qualitative features of T cell function. While numbers of circu-
lating T cells producing IFN-g were not affected, IL-4—producing
T cells were selectively depleted. Therefore, treatment results
in a relative increase in R0pos TH1 cells in the peripheral blood.
The mechanism of CD4pos T cell depletion after treatment
with CD4 mAb is unclear and consequently the basis for the
distinct sensitivities of T cell subpopulations to the CD4 mAb
is hard to define. A role for Fas in the CD4 mAb—induced de-
letion process has been suggested by the observation that mice
lacking a functional Fas receptor do not show a decrease of
CD4pos T cells after treatment with depleting CD4 mAb (48).
In agreement with this, engagement of the CD4 molecule by
CD4 mAb independent of the T cell antigen receptor leads to
a small but rapid increase in cell surface Fas expression and
Fas antigen—dependent apoptosis of T cells (48, 49). Interest-
ingly, when T cells are activated by CD3 antibodies, either in
vitro or in vivo, they become resistant to CD4 mAb—mediated
deletion (50, 51). At first glance it seems paradoxical that acti-
vation of T cells with CD3 mAb, which induces membrane ex-
pression of Fas, renders them insensitive to a deletion process
that involves Fas-mediated apoptosis. However, it should be
noted that when unprimed T cells are activated with CD3 mAb,
they are induced to express Fas but remain insensitive to Fas-
mediated cell death (52). These observations suggest that T
cells can be rescued from CD4 mAb—induced Fas-mediated
deletion by signals, generated via TCR/CD3, which normally
protect antigen-stimulated T cells from apoptosis. If this no-
tion is valid it could explain the finding that murine and human
T cells with membrane characteristics of activation (including
Fas expression) are relatively resistant to depleting CD4 mAb
(43, 53).
Figure 4. CD3pos T cells producing the TH1-type cytokine IFN-g (a) 
are not affected by CD4 mAb treatment, while there is a decline in 
the number of CD3pos T cells producing the TH2-type cytokine IL-4 
(b). Results are expressed as the mean number of CD3pos T cells pro-
ducing either of the two cytokines. Open circles represent the pla-
cebo-treated group and closed triangles represent the CD4 mAb—
treated group. For both parameters the difference between the two 
groups is not significant. The ratio of TH1/TH2-type cells is increased 
after CD4 mAb treatment (P 5 0.035).
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Treatment with the cM-T412 mAb did not have any effect
on disease activity in our group of MS patients as measured by
the number of active lesions on monthly gadolinium-enhanced
MRI over 9 mo (32). Although phase I clinical trials seemed to
be promising (24, 27—29) also in other chronic human autoim-
mune diseases, little or no clinical effect of treatment with
CD4 antibodies could be demonstrated in placebo-controlled
phase II clinical trials (31, 32, 54). The absence of clinical bene-
fit differs markedly from the encouraging results that have
been obtained in experimental model systems for autoimmu-
nity. An important point in the explanation for this discrep-
ancy seems to be the timing of the administration of the CD4
antibody in relation to the stage of the disease process. In most
of the animal models where this kind of treatment is success-
ful, the antibody was given during the period of disease induc-
tion (13, 19, 55). In these models, development of disease is
probably dependent on the recruitment of naive T cells upon
antigenic stimulation. Therefore, it is conceivable that treat-
ment is effective, considering the fact that naive cells are pref-
erentially deleted by the antibody. In agreement with the re-
cent observations in various patient groups, in animal models
administration of CD4 mAb has been unsuccessful in the
treatment of already established disease (18, 56—58). Appar-
ently, ongoing immune responses in vivo are not effectively in-
fluenced by the administration of depleting CD4 mAb. In
agreement with this, our results show that depleting CD4 mAb
does not affect the cell type most strongly implicated in the
pathogenesis of human autoimmune disease, i.e., IFN-g—pro-
ducing TH1-type cells. Future therapies for chronic inflamma-
tory T cell—mediated diseases have to take into account that in-
tervention in ongoing immune responses must be directed at
the primed TH1 T cell subset.
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